Brems-Eskildsen, A. S.5; Linnet, S5; Luczak, Adam Andrzej1; Nielsen, H. A.5; Vestlev, P. M.5; Jensen, B. B.5; Hilling, T.5; Dongsgaard, T.5; Jensen, C. B.5; Neimann, J.5; Nygaard, A. B.5; Langkjer, S. T.5
1 The Faculty of Medicine, Aalborg University, VBN2 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN3 Klinik Kirurgi og Kræftbehandling, The Faculty of Medicine, Aalborg University, VBN4 Kræftbehandling (Onkologi), The Faculty of Medicine, Aalborg University, VBN5 unknown
A living condition for haematological patients treated with chemotherapy
Introduction: Survival of myeloma patients has increased in recent years, but about 20 % of the patients die in the first year after diagnosis. Infections and renal failure are major causes of death, and if not fatal these complications often result in delays of anti-myeloma treatment, progressive disease and death. Many myeloma patients are old with co-morbidities that make them vulnerable, and the disease often causes hypo-gammaglobulinemia and renal failure that may affect patients of all ages. Frailty due to disease-associated factors, high age or co-morbidity has attracted more interest in recent years with the hope that appropriate interventions may improve the patient's survival and quality of life. Objectives: To apply a systematic, prospective assessment of frailty in newly diagnosed myeloma patients, and to reassess the patients at 3, 6 and 12 months to see how appropriate interventions has influenced the patient's survival and quality of life. Methods: A prospective collection of data that reflects disease manifestations and allows assessment of frailty and QoL according to internationally validated scoring systems. Tailored interventions will be implemented to compensate for frailty and improve QoL. Results: A scoring system has been developed that will enable us to determine disease severity, frailty and QoL at diagnosis and after 3, 6 and 12 months of interventions. Conclusions: A systematic, prospective assessment of myeloma patient's disease manifestations, frailty and symptoms will probably allow us to tailor interventions that best meet the patient's needs.
Supportive Care in Cancer, 2015, Vol 23, Issue Suppl 1
*myeloma *patient *human *neoplasm survival morbidity death kidney failure diagnosis scoring system quality of life hope disease severity infection; *rehabilitation *cancer patient *human *neoplasm rehabilitation center patient heart disease quality of life cardiac patient solid mortality learning hospitalization diagnosis economic aspect cancer survivor; *overall survival *patient *human *neoplasm *Charlson Comorbidity Index stereotactic body radiation therapy comorbidity lung cancer non small cell lung cancer scoring system medical record review physician survival control group histology gender follow up smoking tumor volume data base; *hypothyroidism *radiotherapy *neoplasm thyroid gland neck human patient risk factor surgery radiation radiation dose planning model chemotherapy breast cancer subclinical hypothyroidism Hodgkin disease head and neck squamous cell carcinoma data extraction treatment planning thyroid function risk prediction tissues; *neoplasm *risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity platinum derivative enzyme DNA; *osteoporosis *chemotherapy *breast cancer *neoplasm *risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray imaging cancer chemotherapy prednisolone corticosteroid marker calcium vitamin D; *human *neoplasm *nurse *patient *skill *sexuality *hematology *oncology sexual dysfunction conversation health practitioner prevalence sexual orientation society cancer therapy interview sexual function literature counseling coping behavior; *overall survival *radiotherapy *non small cell lung cancer *neoplasm human patient survival radiation chemotherapy histology lung function thorax tumor squamous cell carcinoma lung cancer gender world health organization; *head and neck cancer *radiation *neoplasm mucosa inflammation risk proportional hazards model acceleration human regression analysis log rank test patient radiotherapy intensity modulated radiation therapy; *febrile neutropenia *cancer patient *human *neoplasm male female chemotherapy patient cerebrospinal fluid drug dose reduction risk aged prostate diagnosis Denmark prospective study ovary cancer university hospital oncology retrospective study density prognosis adverse drug reaction *granulocyte colony stimulating factor; *salivary gland function *radiation dose *salivary gland *radiotherapy *head and neck cancer *neoplasm salivation xerostomia stimulus chewing gum radiotherapy planning system side effect flow rate questionnaire prescription drug megadose human patient submandibular gland pilot study food saliva sugar; *central venous catheter *bloodstream infection *therapy *acute lymphoblastic leukemia *cohort analysis *Denmark *neoplasm human patient risk child attributable risk diagnosis death pediatric hospital confidence interval population high risk population neutropenia Gram positive infection; *side effect *human *retrospective study *neoplasm *eye disease patient eye non small cell lung cancer tear flow blurred vision conjunctivitis Denmark oncology toxicity quality of life university hospital clinical practice dry eye palliative therapy swelling skin *pemetrexed; *rehabilitation *interview *oncology ward *nursing *neoplasm human nurse patient intuition hospitalization oral communication hematology ward skill oncology verbal communication communication skill nursing competence questionnaire interpersonal communication; *radiotherapy *cohort analysis *larynx cancer *cancer patient *human *neoplasm *tobacco use smoking lowest income group diagnosis statistics head and neck cancer data base diseases tobacco primary tumor treatment response prognosis logistic regression analysis Denmark risk tobacco consumption patient world health organization; *human *cancer patient *neoplasm *spouse *radiotherapy *head and neck cancer patient diseases physician child friend hospital memory nutrition information processing; *human *phase 1 clinical trial *neoplasm *patient *rectum cancer *neuropathy *prevention neurotoxicity chemotherapy allodynia infusion peripheral neuropathy safety phase 2 clinical trial antineoplastic activity adverse drug reaction model toxicity experience controlled study *placebo oxaliplatin fluorouracil protective agent; *hospital infection *neoplasm human patient oncology ward infection ward risk urinary tract diarrhea disease control bacteremia safety health care pneumonia serum hospitalization infection control surgical ward mouth hygiene prevention immune system; *neoplasm *human *vein thrombosis *patient thrombosis cancer patient risk questionnaire morbidity lung cancer cancer prevention death male prevention female